山外山(688410.SH):預計2024年度歸母淨利潤同比減少58.87%到64.01%
格隆匯1月19日丨山外山(688410.SH)發佈公吿,經財務部門初步測算,預計2024年年度實現歸屬於母公司所有者的淨利潤為7,000.00萬元到8,000.00萬元,與上年同期(法定披露數據)相比,同比減少58.87%到64.01%。預計2024年年度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤為6,000.00萬元到7,000.00萬元,與上年同期(法定披露數據)相比,同比減少60.25%到65.93%。
公吿表示,2023年度由於重症能力建設政策的推動,公司高毛利率產品--連續性血液淨化設備(CRRT)的銷售收入處於較高水平,2024年CRRT銷售收入迴歸常態。若剔除該偶發性因素的影響,公司的2024年營業收入較上年同期預計有所增長。公司堅持實施“國內+國際”雙輪驅動的戰略發展模式,通過不斷優化產品、提升服務質量,保持公司在行業內的領先地位。儘管國內醫療器械招投標活動因市場政策因素出現了短期延遲,但公司並未因此受阻,根據公開數據顯示,在2024年第三季度,公司血液透析機在市場採購數量佔比位列首位,相比去年同期的第四名,實現了顯著的躍升。公司還不斷加強國際營銷團隊建設,積極拓展海外市場,海外市場正逐漸成為公司重要利潤增長點,2024年境外收入預計有所提升。
此外,公司持續加強科技創新能力的建設,2024年的研發投入較上年同期預計大幅增長,研發投入的增加雖然對淨利潤產生了一定影響,但長遠來看,將為公司的持續發展和市場競爭力提升奠定堅實基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.